The cost-effectiveness of different biologic therapies can be an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this study was to compare drug and adverse event costs and cost per successful clinical response with tocilizumab (TCZ) monotherapy vs adalimumab (ADA) monotherapy in patients with RA in a phase 4 clinical trial. Methods: Patients received either TCZ intravenously every 4 weeks or ADA subcutaneously every 2 weeks for 24 weeks. Drug and administration costs were based on wholesale acquisition costs and the Centers for Medicare and Medicaid, respectively. Outcomes included patient-level drug costs, cost of hospitalization due to adverse events, and cost per response. Cost per response was calculated by dividing the mean drug plus administration cost by the proportion of patients achieving Disease Activity Score in 28 joints (DAS28) \ 2.6 (remission) or 20%, 50%, or 70% improvement in response per the American College of Rheumatology (ACR20/50/70). Hospitalization costs were calculated using the daily hospital cost and number of hospital days. Results: Among the 163 patients treated with TCZ and 162 patients treated with ADA, mean total drug and administration costs per patient over 24 weeks were $18,290.60 and $25,623.10, respectively. Mean drug and administration costs per each clinical response achieved were lower with TCZ than with ADA (DAS28 \ 2.
Key Summary Points
Why carry out this study?
The cost-effectiveness of different biologic therapies can be an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA) This analysis compared drug and adverse event costs and cost per successful clinical response with tocilizumab (TCZ) monotherapy vs adalimumab (ADA) monotherapy in patients with RA in a phase 4 clinical trial (ADACTA)
What was learned from this study?
Using data from the ADACTA trial, this analysis found that the cost to achieve clinical response was lower in patients with RA who received TCZ monotherapy than in those who received ADA monotherapy In addition, hospitalization costs were lower in patients who received TCZ than in those who received ADA
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint pain, swelling, and stiffness. RA is associated with substantial costs resulting from direct sources, including drug therapy and hospitalization-related expenses, and indirect sources such as reduced productivity [1, 2] . One of the largest components of total RA costs is drug expenses, which have risen in response to the increased use and availability of biologic disease-modifying antirheumatic drugs (DMARDs) to treat RA [2, 3] . Thus, comparisons of the economic value of different biologic therapies can be an important consideration in guiding treatment decisions for patients with RA.
Tocilizumab (TCZ) is a humanized monoclonal antibody that blocks the interleukin-6 receptor and is approved for the treatment of patients with moderate to severe RA who have had an inadequate response to at least one DMARD [4] . TCZ has been shown to be safe and effective when administered as monotherapy [5] [6] [7] or in combination with methotrexate (MTX) [6, 8, 9] . The anti-tumor necrosis factor agent (aTNF) adalimumab (ADA) is a fully human monoclonal antibody that is approved for the treatment of patients with moderate to severe RA either alone or in combination with DMARDs [10] and recommended for use after an inadequate response to at least one DMARD [11, 12] .
The efficacy of these two biologics was evaluated in the ADACTA trial, a 24-week randomized controlled phase 4 superiority study that compared TCZ monotherapy with ADA monotherapy in patients with RA who were intolerant of MTX or who were inappropriate for continued MTX treatment [7] . This study demonstrated that TCZ monotherapy was more effective than ADA monotherapy in reducing the signs and symptoms of RA over 24 weeks.
Few studies have compared the cost-effectiveness of TCZ and ADA in patients with RA. Furthermore, hospitalization costs are often excluded from analyses of the cost-effectiveness of DMARDs [13, 14] . The objective of this study was to determine the cost per successful outcome in patients with RA who received TCZ or ADA using data from the ADACTA study.
METHODS

Patient Population
The study population for this analysis was the intent-to-treat population from ADACTA, a randomized, double-blind, multicenter superiority study that compared the efficacy of intravenously administered (IV) TCZ 8 mg/kg every 4 weeks (n = 163) with that of subcutaneously administered (SC) ADA 40 mg every 2 weeks (n = 162) for 24 weeks in patients with active RA [7] . The inclusion criteria in the ADACTA trial have been described in detail [7] . Briefly, patients were aged 18 years or more, had severe RA for at least 6 months, were intolerant of MTX or were inappropriate candidates for continued MTX treatment, and had not received a prior biologic. Patients were required to have an erythrocyte sedimentation rate of greater than 28 mm/h or C-reactive protein level of at least 1.0 mg/dL during screening and a Disease Activity Score in 28 joints (DAS28) greater than 5.1, swollen joint count of at least 6, and tender joint count of at least 8 (66/68 joint count) at baseline.
This retrospective analysis used data from the ADACTA study; the ADACTA study protocol was approved by an ethics committee or institutional review board at each participating center and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
Data Source
Drug costs were obtained from Ana-lySource-First Databank [15] and were based on wholesale acquisition cost (WAC) drug prices (July 2018). Administration costs (IV TCZ only) were based on the Centers for Medicare and Medicaid 2018 Healthcare Common Procedure Coding System (HCPCS) code 96413. The daily cost of hospitalization (private and nonprivate) was based on the American Hospital Association 2015 report, updated to 2018.
Study Outcomes
Mean patient-level drug costs and cost of hospitalization due to adverse events (AEs) were assessed at 24 weeks. For TCZ, drug costs were reported as $436.80 per 80 mg (4 mL) vial based on weight at baseline (dosed at 10 kg/vial, rounded up to next higher vial), and administration costs were reported as $145.00 for each infusion. For ADA, drug costs were reported as $2436.00 per 40 mg, with no costs associated with administration. To estimate hospitalization costs for each biologic, the total cost was calculated as the number of hospital days per group multiplied by the daily cost of hospitalization. The daily cost of hospitalization (private and nonprivate) was based on the American Hospital Association 2016 report, updated to 2018 using the Consumer Price Index for health care for 2017 (2.46%) and 2018 (2.4%):
($2338 9 1.0246) 9 1.024 = $2453. Cost per response was evaluated for each drug using DAS28 remission criteria (DAS28 \ 2.6) and 20%, 50%, or 70% improvement in response per the American College of Rheumatology (ACR20/50/70). Cost per response was calculated by dividing the mean drug plus administration cost by the proportion of patients achieving DAS28 \ 2.6 (remission), ACR20, ACR50, or ACR70.
In a secondary analysis, the number needed to treat (NNT) was also calculated.
RESULTS
Among the 163 patients included in the TCZ group, the total drug and administration costs were $2,981,372. For the 162 patients included in the ADA group, the total drug and administration costs were $4,150,944. The mean drug and administration cost per patient was $18,290.60 in the TCZ group and $25,623.10 in the ADA group.
In the TCZ group, five patients were hospitalized for six AEs for a total of 32 days. The total hospitalization costs among patients treated with TCZ were estimated as $78,496, for a mean cost per patient of $484.50 (Table 1 ). In the ADA group, five patients were hospitalized for eight AEs for a total of 43 days. The total hospitalization cost among ADA-treated patients was estimated as $105,479, for a mean cost per patient of $651. 10 .
In ADACTA, a significantly higher proportion of patients who received TCZ monotherapy achieved DAS28 \ 2.6, ACR20, ACR50, or ACR70 at 24 weeks than those who received ADA monotherapy (Fig. 1) [7]. Mean cost per response at 24 weeks was numerically higher in patients who received ADA than in those who received TCZ for DAS28 \ 2.6 ($244,174 vs $45,868), ACR20 ($51,887 vs $28,127), ACR50 ($92,244 vs $38,720), and ACR70 ($143,136 vs $56,253) (Fig. 2) .
The NNT analysis showed that there was an additional responder for every 3.4, 6.4, 5.2, and 6.8 patients treated with TCZ compared with patients treated with ADA for DAS28 \ 2.6, ACR20, ACR50, or ACR70, respectively.
DISCUSSION
This analysis investigated the cost per response of TCZ monotherapy and ADA monotherapy in Several studies evaluated the cost-effectiveness of TCZ and ADA in patients with RA. The Institute for Clinical and Economic Review reported that TCZ IV monotherapy was less costly and more effective than ADA [14] . In addition, a US-based assessment of annual treatment-related (drug plus administration) costs estimated that the cost per ACR20 responder with SC ADA was numerically higher than the cost per responder with SC TCZ when both biologics were administered as monotherapy ($86,096 vs $62,690) [16] . Despite varied methodologies and patient populations and differences in TCZ use, these studies largely support our results and suggest that IV or SC TCZ monotherapy is a more cost-effective treatment than ADA monotherapy. The present findings are also aligned with a prior comparison of the cost-effectiveness of TCZ vs ADA using data from the ADACTA trial, in which a model-based analysis of lifetime cost-effectiveness showed that, despite the higher treatmentrelated costs (drug acquisition, administration, and monitoring) of TCZ monotherapy compared with ADA monotherapy ($15,636 vs $13,553 at 6 months), TCZ was projected to be more cost-effective than ADA, with an incremental cost-effectiveness ratio of $36,944 per quality-adjusted life-year [13] .
Although the concomitant use of conventional synthetic DMARDs (csDMARDs) is recommended with aTNFs (such as ADA) owing to their ability to reduce immunogenicity and increase efficacy [12, 17, 18] , real-world studies have shown that as many as 25-45% of patients use biologic DMARDs as monotherapy (no concomitant csDMARDs) [19] [20] [21] [22] . The results of the present study, along with the proven efficacy and safety of both IV and SC TCZ, demonstrate the value of TCZ for patients who cannot tolerate or prefer not to use MTX. Future studies utilizing registry or claims data with longer follow-up of patients typically treated in routine clinical practice (i.e., multiple comorbidities) are warranted to confirm these results.
This study has some limitations. This analysis was based on wholesale acquisition cost prices and did not consider real-world treatment patterns or any contracted discounts or rebates provided by manufacturers. In addition, as our analysis was based on ADACTA data assessing clinical response rate at 24 weeks of treatment, this study did not account for longer duration of treatment or treatment with a different dosage and/or frequency of administration. This analysis was also limited to IV TCZ treatment and did not evaluate costs for SC TCZ treatment. However, comparable efficacy and safety between SC and IV TCZ have been shown in clinical trials [23] [24] [25] , and comparable effectiveness with SC and IV TCZ has been shown in a real-world setting [23] . Finally, it is possible that hospitalization rates reported in clinical trials such as ADACTA may differ from those observed in routine clinical practice.
CONCLUSIONS
Using data from the ADACTA trial, this analysis found that the cost to achieve all 4 clinical responses was lower in patients with RA who received TCZ monotherapy than in those who received ADA monotherapy. In addition, hospitalization costs were lower in patients who received TCZ than in those who received ADA.
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